Nameko

Metadata

Regulatory Status

Japan

• Status: Widely cultivated and consumed as a common edible mushroom. Nameko is one of the most popular culinary mushrooms in Japan, with large-scale commercial cultivation primarily on sawdust-based substrates.
• Japanese Pharmacopoeia: Not listed.
• Traditional use: Long history as a culinary mushroom in soups (particularly miso soup) and simmered dishes. Not formally classified as a medicinal mushroom in the Japanese kampo tradition, though its consumption is associated with general health maintenance.

China

• Status: Cultivated and consumed as an edible mushroom, known as Hua Gu or Huazhong Hua Gu.
• Chinese Pharmacopoeia: Not listed as an official drug.
• Traditional use: Used in Chinese folk medicine as a food-medicine with general tonic and anti-inflammatory properties. Most bioactive research on nameko polysaccharides has been conducted by Chinese research groups.

United States

• FDA GRAS status: No GRAS determination.
• Dietary supplement: Not widely marketed as a dietary supplement in the US. Available primarily as a culinary mushroom in specialty markets.

European Union

• Novel food status: No specific novel food authorization. Nameko is consumed as a culinary mushroom in some EU markets but is not widely established.
• EMA/HMPC: No monograph or assessment report.

Conditions & Indications

Primary: Immune Modulation (Preclinical Evidence Only)

• Dendritic cell regulation: Nameko polysaccharide PNPS-1 has been shown to modulate dendritic cell maturation and function in vitro. The polysaccharide binds TLR2 receptors on bone marrow-derived dendritic cells (BMDCs), inhibiting NF-kB signaling and decreasing expression of maturation markers (CD40, CD80, CD83, CD86). This promotes an anti-inflammatory cytokine profile with increased IL-10 and decreased IL-12 and TNF-alpha production.
• Macrophage activation: Nameko polysaccharides promote macrophage secretory function and enhance phagocytic capacity in cell culture models, consistent with the general immunostimulatory properties of fungal beta-glucans.

Secondary: Anti-Inflammatory Activity (Preclinical Evidence Only)

• In vivo anti-inflammatory effect: Nameko polysaccharides have demonstrated significant anti-inflammatory activity in rodent paw edema models, with activity comparable to standard anti-inflammatory agents at tested doses.
• NF-kB pathway suppression: The mechanism involves downregulation of MyD88, TRAF6, TIRAP, IRAK1, IKKbeta, and NF-kB subunit expression, with decreased IKKbeta and p65 protein levels in dendritic cells.

Secondary: Hypolipidemic and Antioxidant Effects (Preclinical Evidence Only)

• Lipid-lowering effects: Nameko polysaccharides have shown hypolipidemic activity in hyperlipidemic rat models, reducing total cholesterol and triglyceride levels after oral administration.
• Antioxidant activity: Both in vitro and in vivo studies demonstrate antioxidant effects, including DPPH radical scavenging, superoxide anion scavenging, and reducing power. Polysaccharides also reduce reactive oxygen species (ROS) in H2O2-induced oxidative stress cell models.

Emerging/Preclinical

• Anti-glycation: Nameko polysaccharides inhibit methylglyoxal-induced glycation damage in vitro, suggesting potential relevance to diabetic complications and aging.
• Photoprotection: Polysaccharides have shown protective effects against UVA-induced photoaging in human dermal fibroblast models, regulating matrix metalloproteinase expression.
• Glucose uptake stimulation: Recent research demonstrates that nameko extract can counteract palmitate-induced insulin resistance in C2C12 myotube cell models, stimulating glucose uptake.
• Wound healing: Nameko polysaccharides promote cell proliferation and migration in L929 fibroblast models while reducing oxidative stress, suggesting potential wound-healing applications.

Mechanism of Action

Primary Mechanisms

1. TLR2-mediated dendritic cell modulation: The purified polysaccharide PNPS-1 binds directly to toll-like receptor 2 (TLR2) on the surface of dendritic cells. This interaction, confirmed by anti-TLR2 antibody blocking experiments, inhibits downstream NF-kB signaling by decreasing the expression of key pathway components (MyD88, TRAF6, TIRAP, IRAK1, IKKbeta, NF-kB1, NF-kB2, RelA). The net effect is inhibition of dendritic cell maturation and a shift toward an anti-inflammatory cytokine profile (increased IL-10, decreased IL-12 and TNF-alpha). This represents an immunomodulatory rather than purely immunostimulant mechanism.

2. Beta-glucan immune activation: The beta-(1,3)/(1,6)-D-glucan backbone of nameko polysaccharides activates innate immune cells through dectin-1 and complement receptor 3 (CR3) signaling, enhancing macrophage phagocytic activity, promoting cytokine secretion, and supporting innate immune surveillance. This pathway is shared with other medicinal mushroom beta-glucans but operates in parallel with the TLR2-mediated anti-inflammatory mechanism.

3. Antioxidant radical scavenging: Nameko polysaccharides scavenge DPPH radicals, superoxide anions, and hydroxyl radicals. The antioxidant activity correlates with the heteropolysaccharide content and molecular weight distribution, with different polysaccharide fractions showing varying degrees of activity. Phosphorylated polysaccharide derivatives show enhanced antioxidant and anti-inflammatory activity compared to native polysaccharides.

Secondary Mechanisms

• Lipid metabolism modulation: Hypolipidemic effects in animal models involve reduction of hepatic cholesterol synthesis and modulation of lipid absorption, though the precise molecular targets have not been fully characterized.
• Anti-glycation: Inhibition of methylglyoxal-induced protein glycation may involve direct trapping of reactive carbonyl species by polysaccharide hydroxyl groups, preventing advanced glycation end-product (AGE) formation.
• MMP regulation: Protection against UVA-induced photoaging involves downregulation of matrix metalloproteinase (MMP-1, MMP-3) expression in dermal fibroblasts, likely through modulation of MAP kinase signaling pathways.

Clinical Evidence Summary

No human clinical trials have been published for nameko mushroom or its extracts as of this writing. All evidence for bioactive properties derives from in vitro cell culture studies and in vivo animal models.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials: This is the most significant limitation. All biological activity data derives from cell culture and animal models, which may not translate directly to human clinical effects.
• Predominance of Chinese research groups: Most studies originate from a relatively small number of research groups in China, with limited independent replication by international investigators.
• Dose translation uncertainty: Effective doses in animal and cell models have not been validated for human oral bioavailability or efficacy.
• Extract heterogeneity: Different studies use various extraction and purification methods, yielding polysaccharide fractions with different molecular weights, compositions, and potentially different biological activities.
• Traditional use is primarily culinary: Unlike many medicinal mushrooms, nameko’s traditional use is predominantly as a food rather than as a medicine, limiting the historical evidence base for therapeutic applications.

Safety Profile

General Assessment

Nameko has an extensive history of safe consumption as a culinary mushroom in Japan and China. It is one of the most widely consumed edible mushrooms in Japan, where it is a standard ingredient in miso soup and other dishes. No adverse effects from culinary consumption have been documented in the literature. Safety data for concentrated extracts at supplemental doses is limited to preclinical toxicology studies.

Contraindications

• Mushroom allergy: Individuals with known allergies to mushrooms or molds should exercise caution. Cross-reactivity with other basidiomycete mushrooms is possible.
• Pregnancy and lactation: No safety data exists for concentrated extracts during pregnancy or lactation. Culinary consumption at normal dietary levels is presumed safe based on traditional use.

Drug Interactions

No drug interactions have been documented. However, based on the preclinical activity profile:

• Immunosuppressants: Theoretical concern that beta-glucan immunostimulatory activity could counteract immunosuppressive therapy. Clinical significance is unknown.
• Lipid-lowering agents: Theoretical additive effect with statins or other lipid-lowering medications based on preclinical hypolipidemic activity.

Side Effects

• No side effects have been reported from culinary consumption.
• No systematic adverse event data from supplemental use, as no human trials have been conducted.

Toxicology

• Nameko is generally recognized as a safe edible mushroom with centuries of culinary use.
• No specific toxicological studies at high supplemental doses have been published.
• The distinctive mucilage coating is non-toxic and constitutes a significant portion of the polysaccharide content.

Clinical Dosage

Culinary Use (Food)

• Fresh fruiting body: No established medicinal dose. Consumed ad libitum as a food in Japan and China, typically 50—150 g fresh weight per serving.
• Dried fruiting body: Approximately 5—15 g dried weight per serving.

Polysaccharide Extracts (Preclinical Only)

• No established human clinical dose. Preclinical animal studies have used:
  • Oral polysaccharide doses of 100—400 mg/kg body weight in rat models (hypolipidemic studies)
  • In vitro concentrations of 25—200 micrograms/mL for cell culture experiments
• These doses cannot be directly translated to human recommendations without pharmacokinetic and clinical dose-finding studies.

Form Selection Guidance

As no clinical evidence supports specific dosing for medicinal use, nameko is best regarded as a healthful culinary mushroom with promising preclinical research. Individuals interested in potential immune-supporting benefits may include nameko as part of a varied diet incorporating multiple medicinal mushroom species. Hot-water preparation (as in soups) would be expected to extract water-soluble polysaccharides effectively.

Sources

• Li J, Cai C, Zheng M, Hao J, Li L, Li G. A Polysaccharide from the Culinary-Medicinal Mushroom Pholiota nameko (Agaricomycetes) Inhibits the NF-kB Pathway in Dendritic Cells Through the TLR2 Receptor. Int J Med Mushrooms. 2017;19(1):29-40
• Li J, Cai C, Li J, Li G. Effects of Pholiota nameko polysaccharide on NF-kB pathway of murine bone marrow-derived dendritic cells. Int J Biol Macromol. 2015;78:36-41
• Li J, Li J, Cai C, Li G. Recognization of receptors on bone marrow-derived dendritic cells bound with Pholiota nameko polysaccharides. Int J Biol Macromol. 2014;72:1439-1443
• Li J, Li J, Li G, Cai C. Effects of polysaccharides from Pholiota nameko on maturation of murine bone marrow-derived dendritic cells. Int J Biol Macromol. 2013;62:561-566
• Guo WL, Shi FF, Li L, Dong Q, Chen M, Li CY. Anti-inflammatory activity of polysaccharide from Pholiota nameko. Phytochemistry. 2009;70(8):1023-1027
• Li H, Lu X, Zhang S, Lu M, Liu H. Hypolipidemic effect of the polysaccharide from Pholiota nameko. Nutrition. 2008;24(11-12):1174-1178
• Zhang Y, Li Q, Wang F, Sun H, Zhu J. Pholiota nameko Polysaccharides Promotes Cell Proliferation and Migration and Reduces ROS Content in H2O2-Induced L929 Cells. Foods. 2020;9(2):170
• Li L, Guo W, Liang Y, Gao X, Zhang F, Liu H. Effect of Pholiota nameko Polysaccharides Inhibiting Methylglyoxal-Induced Glycation Damage In Vitro. Molecules. 2021;26(20):6172
• Chen M, Hu L, Li Q. Pholiota nameko Polysaccharides Protect against Ultraviolet A-Induced Photoaging by Regulating Matrix Metalloproteinases in Human Dermal Fibroblasts. Evid Based Complement Alternat Med. 2022;2022:3083541
• Sisti M, Giorgetti G, Ferranti F. Chemical and structural characterization of Pholiota nameko extracts with biological properties. Food Chem. 2017;216:9-15
• Chen H, Zhu Y, Zhang Y, Wu J, Zhao Q, Wei B. Structural characterization and rheological properties of a gel-like beta-D-glucan from Pholiota nameko. Carbohydr Polym. 2017;170:45-52
• Gu Y, Li H, Bao S, Zhang L, Liu N, Luo J. Chemical analysis, moisture-preserving, and antioxidant activities of polysaccharides from Pholiota nameko by fractional precipitation. Int J Biol Macromol. 2019;128:459-466
• Wu Y, Jiang H, Fang X. Structural characterization, antioxidant activity and anti-inflammatory of the phosphorylated polysaccharide from Pholiota nameko. Int J Biol Macromol. 2022;217:456-467
• Aimi T, Yoshida R, Ishikawa M, Bao D, Kitamoto Y. Correct name for “nameko.” Mycoscience. 2005;46(2):146-154
• Fukuda M, Ohno S, De Leonibus E. Japanese “nameko” mushrooms (Pholiota microspora) produced via sawdust-based cultivation exhibit severe genetic bottleneck associated with a single founder. Mycol Prog. 2023;22(3):26

Connections

• Related culinary-medicinal mushrooms: Nameko shares the culinary-medicinal profile common to several East Asian mushrooms. Shiitake (Lentinula edodes) and Maitake (Grifola frondosa) have more extensively studied beta-glucan immunomodulatory activity and provide a benchmark for the type of clinical evidence nameko currently lacks. Enoki (Flammulina velutipes) is another popular Japanese culinary mushroom with emerging medicinal research.
• Beta-glucan immunomodulators: The TLR2/NF-kB pathway modulation demonstrated for nameko polysaccharides is mechanistically related to the immune activity of beta-glucans from Turkey Tail (Trametes versicolor), Maitake, and Oyster Mushroom (Pleurotus ostreatus). However, nameko’s effect on dendritic cells appears to be primarily anti-inflammatory (suppressing maturation, promoting IL-10), contrasting with the more immunostimulant profile of many other mushroom beta-glucans.
• Mucilage-producing fungi: Nameko’s distinctive mucilage layer is rich in heteropolysaccharides and is the primary source of its bioactive polysaccharides. This mucilage-rich profile distinguishes nameko from most other medicinal mushrooms and may contribute to its unique immunomodulatory mechanism.
• Synergy potential: Combining nameko with immunostimulatory mushrooms such as Shiitake (lentinan) or Maitake (D-fraction) could theoretically provide a balanced immunomodulatory effect, pairing dendritic cell-modulating anti-inflammatory activity with innate immune activation. This concept remains untested in clinical or preclinical combination studies.